Novel B Cell Reagents

新型 B 细胞试剂

基本信息

  • 批准号:
    8198172
  • 负责人:
  • 金额:
    $ 43.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-07 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

Memory B cells are key contributors to the indiction and maintenance of humoral immunity. Characterization of the memory B cells response to SIV will be important in an vaccine strategy to elicit a neutralizing antibody response. In this research application we propose to develop reagents to specifically identify macaque memory B cell populations. In proof of principle studies we have produced monoclonal lamprey VLR antibodies that are specific for memory B cells in humans. We propose to develop novel monoclonal VLR antibodies to macaque memory B cells. Unlike mammalian antibodies, the VLR antibodies of the jawless sea lampreys utilize leucine-rich repeats as basic structural units. The radically different protein architecture combined with the large evolutionary distance ofthe sea lamprey allows VLR antibodies to be made that recognize antigenic structures which are not detetcted by mammalian immunoglobulin-based antibodies for structural or tolerogenic reasons. To generate monoclonal VLR antibodies, we will immunize sea lamprey larvae with purified primary B cells or B cell lines. VLR antibody expression libraries will be screened by flow cytometry and monoclonal VLR antibodies that specifically interact with memory B cells or subpopulations thereof will be used as affinity reagents to identify the antigen recognized by the VLR antibody. The VLR antibodies from this core will be provided to research groups to analyze the memory B cell responses to vaccination or SIV challenge. In a complementary approach, we will generate conventional mammalian monoclonal antibodies to FCRL4, an immunoreceptor that In humans is expressed by a subpopulation of mucosa associated memory B cells with enrichment in antibody specificity for the HIV gp120 protein. A fusion protein consisting ofthe extracellular domain of FCRL4 fused to the Fc-domain of IgG will serve as the immunogen and the specific monoclonal antibodies will be identified by flow cytometry. The long term goal of these studies is to generate novel reseach reagents that will facilitate the analysis of memory B cells responding to SIV challenge or vaccination.
记忆B细胞是指示和维持体液免疫的关键因素。表征 记忆B细胞对SIV的反应在疫苗策略中将是重要的,以诱导中和抗体 回应。在这项研究应用中,我们建议开发专门识别猕猴的试剂 记忆B细胞群。在原理研究的证明中,我们已经制造了单克隆性七鳃鳗VLR 针对人类记忆B细胞的抗体。我们建议开发新的单克隆性VLR 猕猴记忆B细胞的抗体。与哺乳动物抗体不同,无颌海的VLR抗体 七鳃鳗利用富含亮氨酸的重复序列作为基本结构单位。截然不同的蛋白质结构 结合海鳗进化的巨大距离,可以制造出VLR抗体 识别未被哺乳动物免疫球蛋白抗体检测的抗原结构 结构性或耐受性原因。为了产生单抗VLR,我们将免疫海鳗 具有纯化的原代B细胞或B细胞系的幼虫。VLR抗体表达文库将通过Flow进行筛选 与记忆B细胞或亚群特异相互作用的细胞术和VLR单抗 其将被用作亲和试剂来鉴定VLR抗体识别的抗原。VLR 来自这个核心的抗体将被提供给研究小组,以分析记忆B细胞对 接种疫苗或SIV挑战。在一个互补的方法中,我们将产生传统的哺乳动物 抗FCRL4的单抗是一种免疫受体,在人类中由以下亚群表达 粘膜相关记忆B细胞,其对HIV gp120蛋白具有丰富的抗体特异性。一个 由FCRL4胞外区与免疫球蛋白Fc区融合而成的融合蛋白将作为 免疫原和特异性单抗将通过流式细胞仪进行鉴定。从长远来看 这些研究的目标是产生新的研究试剂,以促进对记忆B细胞的分析 应对SIV挑战或接种疫苗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Max Dale Cooper其他文献

Max Dale Cooper的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Max Dale Cooper', 18)}}的其他基金

T Cell Differentiation and Diversification in Jawless Vertebrates
无颌脊椎动物的 T 细胞分化和多样化
  • 批准号:
    9897541
  • 财政年份:
    2017
  • 资助金额:
    $ 43.9万
  • 项目类别:
T Cell Differentiation and Diversification in Jawless Vertebrates
无颌脊椎动物的 T 细胞分化和多样化
  • 批准号:
    10623934
  • 财政年份:
    2017
  • 资助金额:
    $ 43.9万
  • 项目类别:
Characterization of an Alternative Adaptive Immune System in Hagfish
盲鳗替代适应性免疫系统的表征
  • 批准号:
    8762010
  • 财政年份:
    2014
  • 资助金额:
    $ 43.9万
  • 项目类别:
Characterization of an Alternative Adaptive Immune System in Hagfish
盲鳗替代适应性免疫系统的表征
  • 批准号:
    9040973
  • 财政年份:
    2014
  • 资助金额:
    $ 43.9万
  • 项目类别:
Novel B Cell Reagents
新型 B 细胞试剂
  • 批准号:
    8516871
  • 财政年份:
    2013
  • 资助金额:
    $ 43.9万
  • 项目类别:
Definition of an Ancient T cell-like System in Lampreys
七鳃鳗中古代 T 细胞样系统的定义
  • 批准号:
    8601715
  • 财政年份:
    2012
  • 资助金额:
    $ 43.9万
  • 项目类别:
Definition of an Ancient T cell-like System in Lampreys
七鳃鳗中古代 T 细胞样系统的定义
  • 批准号:
    8219356
  • 财政年份:
    2012
  • 资助金额:
    $ 43.9万
  • 项目类别:
Definition of an Ancient T cell-like System in Lampreys
七鳃鳗中古代 T 细胞样系统的定义
  • 批准号:
    8434108
  • 财政年份:
    2012
  • 资助金额:
    $ 43.9万
  • 项目类别:
Comparison of B Cell Differentiation in Mice and Humans
小鼠和人类 B 细胞分化的比较
  • 批准号:
    7918590
  • 财政年份:
    2009
  • 资助金额:
    $ 43.9万
  • 项目类别:
Characterization of Lamprey B cells and Antibodies
七鳃鳗 B 细胞和抗体的表征
  • 批准号:
    9914078
  • 财政年份:
    2007
  • 资助金额:
    $ 43.9万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 43.9万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 43.9万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 43.9万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.9万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 43.9万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 43.9万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 43.9万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 43.9万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 43.9万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 43.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了